Natixis Advisors LLC Acquires New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Natixis Advisors LLC acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 12,060 shares of the biopharmaceutical company's stock, valued at approximately $544,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 270 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of PTC Therapeutics in the 4th quarter worth approximately $68,000. R Squared Ltd purchased a new position in shares of PTC Therapeutics during the fourth quarter valued at approximately $79,000. KBC Group NV increased its stake in shares of PTC Therapeutics by 36.4% during the fourth quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock valued at $137,000 after buying an additional 813 shares during the period. Finally, Savant Capital LLC bought a new position in shares of PTC Therapeutics during the fourth quarter valued at approximately $210,000.

Analyst Ratings Changes

Several analysts recently weighed in on PTCT shares. Barclays lifted their price target on shares of PTC Therapeutics from $45.00 to $56.00 and gave the company an "equal weight" rating in a report on Tuesday, December 3rd. Citigroup lifted their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company a "sell" rating in a research note on Wednesday, February 12th. StockNews.com downgraded shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Bank of America raised PTC Therapeutics from an "underperform" rating to a "neutral" rating and lifted their price objective for the company from $41.00 to $55.00 in a research report on Tuesday, March 11th. Finally, The Goldman Sachs Group increased their target price on PTC Therapeutics from $32.00 to $42.00 and gave the stock a "sell" rating in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $63.77.

Remove Ads

PTC Therapeutics Stock Down 6.0 %

PTCT traded down $3.28 during mid-day trading on Monday, reaching $50.96. 1,918,753 shares of the company traded hands, compared to its average volume of 783,548. The company's fifty day moving average price is $51.18 and its 200-day moving average price is $45.37. The stock has a market capitalization of $4.02 billion, a P/E ratio of -8.58 and a beta of 0.66. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $58.38.

Insider Buying and Selling at PTC Therapeutics

In related news, Director Stephanie Okey sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the sale, the director now directly owns 8,867 shares in the company, valued at approximately $478,818. The trade was a 36.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Pierre Gravier sold 1,168 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $58,516.80. Following the sale, the chief financial officer now directly owns 75,603 shares of the company's stock, valued at approximately $3,787,710.30. This represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,391 shares of company stock worth $2,172,927 in the last three months. 5.50% of the stock is currently owned by company insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.